6533b85bfe1ef96bd12ba171
RESEARCH PRODUCT
Adjuncts for ovarian stimulation: when do we adopt “orphan indications” for approved drugs?
R. Jeffrey ChangDominique De ZieglerDavid R. MeldrumRichard T. ScottWilliam B. SchoolcraftAntonio Pellicersubject
Drugendocrine systemmedicine.medical_specialtyOrphan Drug ProductionResearch methodologymedia_common.quotation_subjectFertilization in VitroReproductive technologyAcide acétylsalicyliqueHealth servicesProstaglandin-Endoperoxide SynthaseOvulation InductionHumansMedicineIntensive care medicinemedia_commonGynecologyAspirinHuman Growth Hormonebusiness.industryObstetrics and GynecologyErgot DerivativesEstrogensMetforminReproductive MedicineDopamine AgonistsAndrogensFemaleFertility agentsLeuprolidebusinessContraceptives OralPolycystic Ovary Syndromedescription
Several drugs, shown to be safe for other uses, have proven to be highly effective adjuncts for ovarian stimulation. The authors evaluate these "orphan" indications and make recommendations so that more patients will benefit from their use.
year | journal | country | edition | language |
---|---|---|---|---|
2009-07-01 | Fertility and Sterility |